<s id="wsj_0932.1"> 23
1 	 0 	 NP[nb]/N 	 1 	 amount The
1 	 2 	 (NP\NP)/NP 	 1 	 amount of
1 	 12 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 amount can
1 	 14 	 S[pss]\NP 	 1 	 amount increased <XB>
3 	 2 	 (NP\NP)/NP 	 2 	 blood of
3 	 7 	 (S[b]\NP)/NP 	 2 	 blood donate <XU>
3 	 9 	 (S[b]\NP)/NP 	 2 	 blood store <XU>
5 	 4 	 N/N 	 1 	 patients surgical
5 	 6 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 patients can
5 	 7 	 (S[b]\NP)/NP 	 1 	 patients donate <XB>
5 	 9 	 (S[b]\NP)/NP 	 1 	 patients store <XU>
7 	 6 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 donate can
7 	 10 	 ((S\NP)\(S\NP))/NP 	 2 	 donate before
9 	 6 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 store can
9 	 10 	 ((S\NP)\(S\NP))/NP 	 2 	 store before
11 	 10 	 ((S\NP)\(S\NP))/NP 	 3 	 surgery before
13 	 12 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 be can
14 	 13 	 (S[b]\NP)/(S[pss]\NP) 	 2 	 increased be
14 	 15 	 ((S\NP)\(S\NP))/NP 	 2 	 increased by
19 	 18 	 (N/N)/(N/N) 	 2 	 engineered genetically
20 	 15 	 ((S\NP)\(S\NP))/NP 	 3 	 drug by
20 	 16 	 NP[nb]/N 	 1 	 drug the
20 	 17 	 N/N 	 1 	 drug new
20 	 19 	 N/N 	 1 	 drug engineered
22 	 15 	 ((S\NP)\(S\NP))/NP 	 3 	 EPO by
<\s>
<s id="wsj_0932.2"> 20
0 	 5 	 (S[dcl]\NP)/NP 	 1 	 EPO is
3 	 5 	 (S[dcl]\NP)/NP 	 1 	 erythropoietin is
7 	 5 	 (S[dcl]\NP)/NP 	 2 	 protein is
7 	 6 	 NP[nb]/N 	 1 	 protein a
7 	 11 	 (S[dcl]\NP)/NP 	 2 	 protein makes <XU>
10 	 8 	 NP[nb]/N 	 1 	 body the
10 	 9 	 N/N 	 1 	 body human
10 	 11 	 (S[dcl]\NP)/NP 	 1 	 body makes
10 	 13 	 (S[b]\NP)/NP 	 1 	 body stimulate <XB>
13 	 12 	 (S[to]\NP)/(S[b]\NP) 	 2 	 stimulate to
15 	 13 	 (S[b]\NP)/NP 	 2 	 growth stimulate
15 	 14 	 NP[nb]/N 	 1 	 growth the
15 	 16 	 (NP\NP)/NP 	 1 	 growth of
19 	 16 	 (NP\NP)/NP 	 2 	 cells of
19 	 17 	 N/N 	 1 	 cells red
19 	 18 	 N/N 	 1 	 cells blood
<\s>
<s id="wsj_0932.3"> 31
2 	 1 	 (N/N)/(N/N) 	 2 	 engineered genetically
3 	 0 	 NP[nb]/N 	 1 	 version A
3 	 2 	 N/N 	 1 	 version engineered
3 	 4 	 (NP\NP)/NP 	 1 	 version of
3 	 8 	 S[pss]\NP 	 1 	 version developed <XB>
3 	 19 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 version has
3 	 21 	 S[pss]\NP 	 1 	 version marketed <XB>
7 	 4 	 (NP\NP)/NP 	 2 	 protein of
7 	 5 	 NP[nb]/N 	 1 	 protein the
7 	 6 	 N/N 	 1 	 protein human
8 	 9 	 ((S\NP)\(S\NP))/NP 	 2 	 developed by
11 	 9 	 ((S\NP)\(S\NP))/NP 	 3 	 Corp. by
11 	 10 	 N/N 	 1 	 Corp. Amgen
11 	 12 	 (NP\NP)/NP 	 1 	 Corp. of
14 	 12 	 (NP\NP)/NP 	 2 	 Oaks of
14 	 13 	 N/N 	 1 	 Oaks Thousand
16 	 12 	 (NP\NP)/NP 	 2 	 Calif. of
19 	 18 	 (S\NP)/(S\NP) 	 2 	 has recently
20 	 19 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 been has
21 	 20 	 (S[pt]\NP)/(S[pss]\NP) 	 2 	 marketed been
21 	 22 	 ((S\NP)\(S\NP))/NP 	 2 	 marketed by
26 	 22 	 ((S\NP)\(S\NP))/NP 	 3 	 division by
26 	 23 	 NP[nb]/N 	 1 	 division the
26 	 24 	 N/N 	 1 	 division Ortho
26 	 25 	 N/N 	 1 	 division Pharmaceuticals
26 	 27 	 (NP\NP)/NP 	 1 	 division of
30 	 27 	 (NP\NP)/NP 	 2 	 Johnson of
30 	 28 	 N/N 	 1 	 Johnson Johnson
30 	 29 	 N/N 	 1 	 Johnson &
<\s>
<s id="wsj_0932.4"> 16
2 	 0 	 NP[nb]/N 	 1 	 version A
2 	 1 	 N/N 	 1 	 version competing
2 	 3 	 (NP\NP)/NP 	 1 	 version of
2 	 5 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 version is
2 	 6 	 (S[ng]\NP)/(S[pss]\NP) 	 1 	 version being <XB>
2 	 7 	 S[pss]\NP 	 1 	 version developed <XB>
4 	 3 	 (NP\NP)/NP 	 2 	 EPO of
6 	 5 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 being is
7 	 6 	 (S[ng]\NP)/(S[pss]\NP) 	 2 	 developed being
7 	 8 	 ((S\NP)\(S\NP))/NP 	 2 	 developed by
11 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 Inc. by
11 	 9 	 N/N 	 1 	 Inc. Genetics
11 	 10 	 N/N 	 1 	 Inc. Institute
11 	 12 	 (NP\NP)/NP 	 1 	 Inc. in
13 	 12 	 (NP\NP)/NP 	 2 	 Cambridge in
15 	 12 	 (NP\NP)/NP 	 2 	 Mass in
<\s>
<s id="wsj_0932.5"> 9
1 	 0 	 NP[nb]/N 	 1 	 drug The
1 	 2 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 drug is
1 	 3 	 (S[ng]\NP)/(S[pss]\NP) 	 1 	 drug being <XB>
1 	 4 	 (S[pss]\NP)/(S[to]\NP) 	 1 	 drug used <XB>
1 	 7 	 (S[b]\NP)/NP 	 1 	 drug treat <XB>
3 	 2 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 being is
4 	 3 	 (S[ng]\NP)/(S[pss]\NP) 	 2 	 used being
4 	 5 	 (S\NP)\(S\NP) 	 2 	 used primarily
6 	 4 	 (S[pss]\NP)/(S[to]\NP) 	 2 	 to used
7 	 6 	 (S[to]\NP)/(S[b]\NP) 	 2 	 treat to
8 	 7 	 (S[b]\NP)/NP 	 2 	 anemias treat
<\s>
<s id="wsj_0932.6"> 34
2 	 0 	 NP[nb]/N 	 1 	 experiment A
2 	 1 	 N/N 	 1 	 experiment new
2 	 4 	 S[pss]\NP 	 1 	 experiment reported <XB>
2 	 15 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 experiment involved
2 	 16 	 ((S[ng]\NP)/PP)/NP 	 1 	 experiment giving <XB>
4 	 5 	 ((S\NP)\(S\NP))/NP 	 2 	 reported in
7 	 6 	 NP[nb]/N 	 1 	 week this
7 	 8 	 (NP[nb]/N)\NP 	 2 	 week 's
11 	 5 	 ((S\NP)\(S\NP))/NP 	 3 	 Journal in
11 	 8 	 (NP[nb]/N)\NP 	 1 	 Journal 's
11 	 9 	 N/N 	 1 	 Journal New
11 	 10 	 N/N 	 1 	 Journal England
11 	 12 	 (NP\NP)/NP 	 1 	 Journal of
13 	 12 	 (NP\NP)/NP 	 2 	 Medicine of
16 	 15 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 giving involved
17 	 16 	 ((S[ng]\NP)/PP)/NP 	 3 	 injections giving
17 	 18 	 (NP\NP)/NP 	 1 	 injections of
19 	 20 	 (NP[nb]/N)\NP 	 2 	 Amgen 's
21 	 18 	 (NP\NP)/NP 	 2 	 EPO of
21 	 20 	 (NP[nb]/N)\NP 	 1 	 EPO 's
22 	 16 	 ((S[ng]\NP)/PP)/NP 	 2 	 to giving
24 	 22 	 PP/NP 	 1 	 patients to
24 	 23 	 N/N 	 1 	 patients 23
24 	 25 	 (NP\NP)/(S[dcl]\NP) 	 1 	 patients who
24 	 26 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 patients wanted <XB>
24 	 28 	 (S[b]\NP)/NP 	 1 	 patients store <XB>
26 	 25 	 (NP\NP)/(S[dcl]\NP) 	 2 	 wanted who
27 	 26 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to wanted
28 	 27 	 (S[to]\NP)/(S[b]\NP) 	 2 	 store to
29 	 28 	 (S[b]\NP)/NP 	 2 	 units store
29 	 30 	 (NP\NP)/NP 	 1 	 units of
33 	 30 	 (NP\NP)/NP 	 2 	 blood of
33 	 31 	 NP[nb]/N 	 1 	 blood their
33 	 32 	 N/N 	 1 	 blood own
<\s>
<s id="wsj_0932.7"> 13
1 	 0 	 NP[nb]/N 	 1 	 patients The
1 	 2 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 patients began
1 	 3 	 (S[ng]\NP)/NP 	 1 	 patients receiving <XB>
3 	 2 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 receiving began
3 	 9 	 (((S\NP)\(S\NP))\NP)/NP 	 2 	 receiving before
5 	 3 	 (S[ng]\NP)/NP 	 2 	 injections receiving
5 	 4 	 N/N 	 1 	 injections EPO
8 	 6 	 NP/NP 	 1 	 month about
8 	 7 	 NP[nb]/N 	 1 	 month a
8 	 9 	 (((S\NP)\(S\NP))\NP)/NP 	 3 	 month before
12 	 9 	 (((S\NP)\(S\NP))\NP)/NP 	 4 	 surgery before
12 	 10 	 NP[nb]/N 	 1 	 surgery their
12 	 11 	 N/N 	 1 	 surgery scheduled
<\s>
<s id="wsj_0932.8"> 15
0 	 2 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 They began
0 	 3 	 (S[ng]\NP)/NP 	 1 	 They donating <XB>
0 	 9 	 (S[ng]\NP)/NP 	 1 	 They receiving <XB>
2 	 1 	 (S\NP)/(S\NP) 	 2 	 began then
3 	 2 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 donating began
3 	 6 	 ((S\NP)\(S\NP))/N 	 2 	 donating a
4 	 3 	 (S[ng]\NP)/NP 	 2 	 blood donating
6 	 5 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 a twice
7 	 6 	 ((S\NP)\(S\NP))/N 	 3 	 week a
9 	 13 	 ((S\NP)\(S\NP))/N 	 2 	 receiving each
12 	 9 	 (S[ng]\NP)/NP 	 2 	 injection receiving
12 	 10 	 NP[nb]/N 	 1 	 injection an
12 	 11 	 N/N 	 1 	 injection EPO
14 	 13 	 ((S\NP)\(S\NP))/N 	 3 	 time each
<\s>
<s id="wsj_0932.9"> 14
1 	 2 	 (S[dcl]\NP)/NP 	 1 	 tests indicated
2 	 0 	 (S/S)/S[dcl] 	 2 	 indicated If
5 	 2 	 (S[dcl]\NP)/NP 	 2 	 number indicated
5 	 3 	 NP[nb]/N 	 1 	 number a
5 	 4 	 N/N 	 1 	 number low
5 	 6 	 (NP\NP)/NP 	 1 	 number of
8 	 6 	 (NP\NP)/NP 	 2 	 cells of
8 	 7 	 N/N 	 1 	 cells red
10 	 11 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 blood was
10 	 13 	 S[pss]\NP 	 1 	 blood taken <XB>
11 	 0 	 (S/S)/S[dcl] 	 1 	 was If
11 	 12 	 (S\NP)\(S\NP) 	 2 	 was n't
13 	 11 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 taken was
<\s>
<s id="wsj_0932.10"> 30
2 	 0 	 NP[nb]/N 	 1 	 patients The
2 	 1 	 N/N 	 1 	 patients EPO-treated
2 	 3 	 (S[dcl]\NP)/NP 	 1 	 patients donated
3 	 12 	 ((S\NP)\(S\NP))/PP 	 2 	 donated compared
5 	 3 	 (S[dcl]\NP)/NP 	 2 	 average donated
5 	 4 	 NP[nb]/N 	 1 	 average an
5 	 6 	 (NP\NP)/NP 	 1 	 average of
5 	 11 	 NP\NP 	 1 	 average each
8 	 6 	 (NP\NP)/NP 	 2 	 units of
8 	 7 	 N/N 	 1 	 units 5.4
8 	 9 	 (NP\NP)/NP 	 1 	 units of
10 	 9 	 (NP\NP)/NP 	 2 	 blood of
13 	 12 	 ((S\NP)\(S\NP))/PP 	 3 	 with compared
15 	 14 	 (N/N)/(N/N) 	 2 	 4.1 only
16 	 13 	 PP/NP 	 1 	 units with
16 	 15 	 N/N 	 1 	 units 4.1
16 	 17 	 S[pss]\NP 	 1 	 units donated <XB>
17 	 18 	 ((S\NP)\(S\NP))/NP 	 2 	 donated by
21 	 18 	 ((S\NP)\(S\NP))/NP 	 3 	 group by
21 	 19 	 NP[nb]/N 	 1 	 group a
21 	 20 	 N/N 	 1 	 group similar
21 	 22 	 (NP\NP)/NP 	 1 	 group of
24 	 22 	 (NP\NP)/NP 	 2 	 patients of
24 	 23 	 N/N 	 1 	 patients surgical
24 	 25 	 (NP\NP)/(S[dcl]\NP) 	 1 	 patients who
24 	 26 	 (S[dcl]\NP)/NP 	 1 	 patients received <XB>
26 	 25 	 (NP\NP)/(S[dcl]\NP) 	 2 	 received who
29 	 26 	 (S[dcl]\NP)/NP 	 2 	 injection received
29 	 27 	 NP[nb]/N 	 1 	 injection a
29 	 28 	 N/N 	 1 	 injection placebo
<\s>
<s id="wsj_0932.11"> 29
1 	 0 	 NP[nb]/N 	 1 	 volume The
1 	 2 	 (NP\NP)/NP 	 1 	 volume of
1 	 10 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 volume was
1 	 13 	 (S[adj]\NP)\NP 	 1 	 volume higher <XB>
4 	 2 	 (NP\NP)/NP 	 2 	 cells of
4 	 3 	 N/N 	 1 	 cells red
4 	 5 	 S[pss]\NP 	 1 	 cells donated <XB>
5 	 6 	 ((S\NP)\(S\NP))/NP 	 2 	 donated by
9 	 6 	 ((S\NP)\(S\NP))/NP 	 3 	 patients by
9 	 7 	 NP[nb]/N 	 1 	 patients the
9 	 8 	 N/N 	 1 	 patients EPO-treated
10 	 14 	 ((S\NP)\(S\NP))/NP 	 2 	 was per
10 	 28 	 (S[dcl]\S[dcl])\NP 	 1 	 was reported
12 	 11 	 N/N 	 1 	 % 41
12 	 13 	 (S[adj]\NP)\NP 	 2 	 % higher
13 	 10 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 higher was
15 	 14 	 ((S\NP)\(S\NP))/NP 	 3 	 donor per
19 	 17 	 NP[nb]/N 	 1 	 team the
19 	 18 	 N/N 	 1 	 team research
19 	 20 	 (S[ng]\NP)/NP 	 1 	 team representing <XB>
19 	 28 	 (S[dcl]\S[dcl])\NP 	 2 	 team reported
22 	 20 	 (S[ng]\NP)/NP 	 2 	 number representing
22 	 21 	 NP[nb]/N 	 1 	 number a
22 	 23 	 (NP\NP)/NP 	 1 	 number of
24 	 23 	 (NP\NP)/NP 	 2 	 hospitals of
27 	 23 	 (NP\NP)/NP 	 2 	 banks of
27 	 26 	 N/N 	 1 	 banks blood
<\s>
